Citigroup
AVTX icon

Citigroup’s Avalo Therapeutics AVTX Stock Holding History

Citigroup’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,143
Closed -$20.8K – 5948
2025
Q4 		$20.8K Buy
1,143
+743
+186% +$12.5K ﹤0.01% 4859
2025
Q3 		$5.08K Buy
+400
New +$3.44K ﹤0.01% 5228
2022
Q3 		– Sell
-1
Closed -$1K – 5821
2022
Q2 		$1K Hold
1
– – ﹤0.01% 5980
2022
Q1 		$2K Sell
1
-5
-83% -$12.6K ﹤0.01% 6040
2021
Q4 		$30K Buy
6
+4
+200% +$24K ﹤0.01% 5263
2021
Q3 		$13K Buy
2
+1
+100% +$8.11K ﹤0.01% 5397
2021
Q2 		$8K Hold
1
– – ﹤0.01% 5730
2021
Q1 		$9K Sell
1
-1
-50% -$9.45K ﹤0.01% 5676
2020
Q4 		$17K Buy
2
+1
+100% +$6.95K ﹤0.01% 6737
2020
Q3 		$4K Hold
1
– – ﹤0.01% 7093
2020
Q2 		$10K Sell
1
-1
-50% -$7.26K ﹤0.01% 7036
2020
Q1 		$15K Hold
2
– – ﹤0.01% 6846
2019
Q4 		$24K Buy
+2
New +$21.1K ﹤0.01% 6830
2019
Q3 		– Sell
-2
Closed -$22.3K – 7381
2019
Q2 		$33K Sell
2
-4
-67% -$60.6K ﹤0.01% 6791
2019
Q1 		$107K Buy
+6
New +$89.8K ﹤0.01% 5677

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Citigroup's AVTX Position: Q1 2026 in Review

Citigroup sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 1,143 shares — an estimated $20.8K sold.

Citigroup first reported a position in AVTX in Q1 2019 and held it in 15 quarters. The position peaked at $107K in Q1 2019. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Citigroup reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1,143 Avalo Therapeutics shares in Q1 2026, an estimated $20.8K.
  • Citigroup first reported a position in Avalo Therapeutics in Q1 2019 and held it in 15 quarters.
  • Citigroup's Avalo Therapeutics position peaked at $107K in Q1 2019.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.